Literature DB >> 11819709

Morphological study on colonic pathology in ulcerative colitis treated by moxibustion.

Huan-Gan Wu, Li-Bin Zhou, Da-Ren Shi, Shi-Min Liu, Hui-Rong Liu, Bi-Meng Zhang, Han-Ping Chen, Lin-Shan Zhang.   

Abstract

AIM:To observe the therapeutic effect of moxibustion on ulcerative colitis and its influence on the colonic mucosal morphology.
METHODS: Forty-six patients with ulcerative colitis were randomly divided into the moxibustion with herbal medicine underneath group and the western medicine group. Thirty patients were treated with the above moxibustion and 16 patients with Salicylaye fapyridine (SASP).The colonic mucosa of 13 patients in the moxibustion group was observed by colonoscopy before and after the treatment. Mucin was also analyzed by H.E and AB-PAS staining.
RESULTS: Seventeen patients were clinically cured,12 were improved and 1 unchanged in the moxibustion group. In the control group, 5 patients were clinically cured,7 improved and 4 unchanged. Thirteen patients with active UC were taken as the subjects for histopathologic analysis in this study. The colonic mucosal lesions were remarkably improved and the characteristic of the mucin also changed. In most sections, the chronic inflammation of mucosa was geatly ameliorated (P< 0.01). The inflammatory cell infiltratation much decreased and neutrophils, disapeared in most sections (P<0.001). The goblet cells significantly increased (P<0.001); crypt paracrypt abscess or mucosal ulceration was seen(P<0.001).
CONCLUSION: The rate of cure of ulcerative colitis by moxibustion with herbal medicine beneath is superior to that by SASP. This sort of moxibustion can effectively improve the colonic mucosal lesions and restore the proportion of mucoprotein to near normal.

Entities:  

Year:  2000        PMID: 11819709      PMCID: PMC4728275          DOI: 10.3748/wjg.v6.i6.861

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  6 in total

1.  New treatments for inflammatory bowel disease.

Authors:  David S Rampton; D Phil
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

2.  Current medical therapy for ulcerative colitis.

Authors:  Chang-Tai Xu; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  1999-02       Impact factor: 5.742

3.  Study of the mechanisms of acupuncture and moxibustion treatment for ulcerative colitis rats in view of the gene expression of cytokines.

Authors:  Huan-Gan Wu; Li-Bin Zhou; Ying-Ying Pan; Cheng Huang; Han-Ping Chen; Zheng Shi; Xue-Gui Hua
Journal:  World J Gastroenterol       Date:  1999-12       Impact factor: 5.742

4.  Abnormal patterns of mucus secretion in apparently normal mucosa of large intestine with carcinoma.

Authors:  M I Filipe; A C Branfoot
Journal:  Cancer       Date:  1974-08       Impact factor: 6.860

5.  Parkinsonism due to a basal ganglia lacunar state: clinicopathologic correlation.

Authors:  R W Murrow; G D Schweiger; J J Kepes; W C Koller
Journal:  Neurology       Date:  1990-06       Impact factor: 9.910

6.  Mucous secretion in rat colonic mucosa during carcinogenesis induced by dimethylhydrazine. A morphological and histochemical study.

Authors:  M I Filipe
Journal:  Br J Cancer       Date:  1975-07       Impact factor: 7.640

  6 in total
  18 in total

Review 1.  An analysis of 10218 ulcerative colitis cases in China.

Authors:  Xue-Liang Jiang; Hui-Fei Cui
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

2.  Moxibustion treatment modulates the gut microbiota and immune function in a dextran sulphate sodium-induced colitis rat model.

Authors:  Qin Qi; Ya-Nan Liu; Xiao-Ming Jin; Lin-Shuang Zhang; Cun Wang; Chun-Hui Bao; Hui-Rong Liu; Huan-Gan Wu; Xiao-Mei Wang
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

3.  Moxibustion inhibits interleukin-12 and tumor necrosis factor alpha and modulates intestinal flora in rat with ulcerative colitis.

Authors:  Xiao-Mei Wang; Yuan Lu; Lu-Yi Wu; Shu-Guang Yu; Bai-Xiao Zhao; Hong-Yi Hu; Huan-Gan Wu; Chun-Hui Bao; Hui-Rong Liu; Jin-Hai Wang; Yi Yao; Xue-Gui Hua; Hui-Ying Guo; Li-Rong Shen
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

4.  Infrared thermoimages display of body surface temperature reaction in experimental cholecystitis.

Authors:  Dong Zhang; Yuan-Gen Zhu; Shu-You Wang; Hui-Min Ma; Yan-Yan Ye; Wei-Xing Fu; Wei-Guo Hu
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

5.  Distribution of nitric oxide synthase in stomach myenteric plexus of rats.

Authors:  X Peng; J B Feng; H Yan; Y Zhao; S L Wang
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

Review 6.  Moxibustion for ulcerative colitis: a systematic review and meta-analysis.

Authors:  Dong-Hyo Lee; Jong-In Kim; Myeong Soo Lee; Tae-Young Choi; Sun-Mi Choi; Edzard Ernst
Journal:  BMC Gastroenterol       Date:  2010-04-07       Impact factor: 3.067

7.  Effects of Rheum tanguticum polysaccharide on TNBS -induced colitis and CD4+T cells in rats.

Authors:  Li Liu; Zhi-Peng Wang; Chang-Tai Xu; Bo-Rong Pan; Qi-Bing Mei; Yin Long; Jia-Yun Liu; Si-Yuan Zhou
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

8.  Mechanisms of acupuncture and moxibustion in regulation of epithelial cell apoptosis in rat ulcerative colitis.

Authors:  Huan-Gan Wu; Xiao Gong; Li-Qing Yao; Wei Zhang; Yin Shi; Hui-Rong Liu; Ye-Jing Gong; Li-Bin Zhou; Yi Zhu
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

9.  Moxibustion regulates inflammatory mediators and colonic mucosal barrier in ulcerative colitis rats.

Authors:  Tie-Ming Ma; Na Xu; Xian-De Ma; Zeng-Hua Bai; Xing Tao; Hong-Chi Yan
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

10.  Effects of Moxibustion Stimulation on the Intensity of Infrared Radiation of Tianshu (ST25) Acupoints in Rats with Ulcerative Colitis.

Authors:  Xiaomei Wang; Shuang Zhou; Wei Yao; Hua Wan; Huangan Wu; Luyi Wu; Huirong Liu; Xuegui Hua; Peifeng Shi
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-20       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.